HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmeceuticals

This article was originally published in The Rose Sheet

Executive Summary

The market for cosmeceuticals sold across mass, department, specialty and other retailers in the U.S. was estimated to be around $500 mil.-$600 mil. in 2005, according to Karen Young, president of marketing firm The Young Group. Exec presented during the Strategic Research Institute-sponsored Cosmeceuticals meeting in New York City June 8-9. In her presentation "Getting Your Brand Into the Channels That Count," Young noted the Internet remains an excellent means to attract new customers to a brand, and 80% of consumers regularly or occasionally purchase products online...

You may also be interested in...



Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations

Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.

US FDA Eyes Ocular Risks With GlaxoSmithKline’s Myeloma Drug Belantamab

Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

UsernamePublicRestriction

Register

WI964947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel